cannabidivarin and Fragile-X-Syndrome

cannabidivarin has been researched along with Fragile-X-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for cannabidivarin and Fragile-X-Syndrome

Article	Year
Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Cells, 2023, 07-25, Volume: 12, Issue:15 Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the Topics: Animals; Anxiety; Fragile X Mental Retardation Protein; Fragile X Syndrome; Mice; Mice, Knockout	2023

Article

Year

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the

Cells, 2023, 07-25, Volume: 12, Issue:15

Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remains unexplored. Here, we characterized the neurobehavioral effects of CBDV at doses of 20 or 100 mg/kg in the

Topics: Animals; Anxiety; Fragile X Mental Retardation Protein; Fragile X Syndrome; Mice; Mice, Knockout

2023